Peer-influenced content. Sources you trust. No registration required. This is HCN.
JAMA Network
There are no approved medications for the core symptoms of autism spectrum disorder (ASD), socialization and communication difficulties. Did balovaptan, an oral selective vasopressin 1a receptor antagonist, help us get closer to an approved drug?
Pediatrics July 12th 2022
With treatment penetration rates less than 20% for those with serious addictions, this viewpoint offers up a strategic clinical approach that mimics the diabetes field, using the term preaddiction, a commonly understood, motivating term (such as prediabetes) that could engender broader clinical efforts to effect the planned strategy.
Psychiatry July 12th 2022
Psych Congress Network
Watch Dr. Jain discuss his seven tips to help to gauge what is working, what is not working, and where there is room for improvement in treating and managing your adult patients with ADHD.
Psychiatry July 5th 2022
MDLinx
The research shows that chronic pain, inflammatory bowel disease, cancer, and migraines all play a role in the development of mental diseases. Healthcare practitioners should take a careful history and keep in mind comorbidities when treating patients for any of these conditions.
Gastroenterology July 5th 2022
In this Q&A, Dr. Vincent Millischer describes the surprising association between lithium clearance and serum lithium as well as the role that genetics may play in helping to determine the proper lithium dosage for each patient.
ReachMD
In this 30-minute, 0.50 credit CME activity, participants will be better able to define treatment response, remission and treatment resistance in MDD; identify patients with inadequate response to antidepressants who may benefit from treatment modification; select an appropriate next-step treatment strategy for a patient with partial response to an antidepressant; and compare pharmacologic and adverse effect profiles of SGAs approved for adjunctive treatment of MDD.